Although the authors deemed the treatment safe, making any conclusions on its efficacy was challenging, partly because the clinical response was more strongly correlated with the tumor burden at the start of the study than with the actual treatment of EpCAM CAR-T cells. This evidence concerns the gene EPCAM and neoplasm.